Eurofins Technologies announces the launch of reagents for automated isolation of high-quality SARS-CoV-2 RNA (ribonucleic acid) from viral particles of human swab samples. The kits’ magnetic bead-based, automated testing method extracts and isolates virus particles and their respective RNA for subsequent real-time RT-PCR (reverse transcription polymerase chain reaction) analysis by IVD kits.
GSD NovaPrime® RNA Extraction AE1 and AE2 kits are validated for use with KingFisherTM Flex and MGI MGISP-960 automation platforms. Compatibility testing with several other open-platform extraction instruments is underway.
Eurofins Technologies announces the launch of CE-IVD marked rapid point-of-care testing devices to identify a person’s past exposure to COVID-19 (SARS-CoV-2) in only 10 minutes. The serology-based, finger-prick tests detect virus antibodies with a sensitivity of 94.5% from 19 days following the onset of symptoms.
Eurofins Technologies, a supplier of test kits and systems for laboratory analyses, announces that its ELISA assay (enzyme-linked immunosorbent assay) for the detection of gluten, SENSISpec Ingezim Gluten R5, has been granted AOAC Research Institute Performance Tested MethodsSM status (AOAC Cert. No. 052005) for use with gluten-free bread, oat flour and stainless steel surfaces.
The assay was developed by Eurofins Ingenasa, a biotechnology company with more than 20 years of experience in food allergen analysis and a member of Eurofins Technologies’ group of companies.
Eurofins Technologies announces the launch of a serology-based total antibody (IgG, IgA and IgM) detection ELISA assay for indirect diagnostic of past exposure to COVID-19. The development of the assay has been led by Eurofins Ingenasa, a Eurofins Technologies company involved in the development of diagnostic tests supporting the control of infectious diseases for over 35 years in veterinary and more recently in human diagnostics.
While molecular diagnostic techniques (PCR) are a direct indicator of the COVID-19 disease, serological tests determine whether a person has been exposed to the infection and has therefore developed antibodies to SARS-CoV-2.
Eurofins Technologies announces the launch of its CE-IVD marked multiplex Real-Time RT-PCR (reverse-transcriptase polymerase chain reaction) assay for the direct qualitative pathogen detection of the novel coronavirus (SARS-CoV-2). Particularly in the early phase of COVID-19 infection, the direct and precise diagnostic of the pathogen is key. PCR is the method of choice to detect acute coronavirus infections.
The development of the assay has been spearheaded by affiliate companies Gold Standard Diagnostics Inc., VIROTECH Diagnostics GmbH and NovaTec Immundiagnostica GmbH.
Eurofins GeneScan Technologies is offering a new kit as part of its VIRSeek Solution to detect SARS-CoV-2 (Coronavirus) in swabs of environmental surfaces.
Join our webinar to know more about our VIRSeek SARS-CoV-2 Coronavirus Environmental Testing Solutions!
Due to the SARS-CoV-2 virus’ potential for a prolonged tenacity on surfaces, transmission through contaminated surfaces is being investigated as a possible route of exposure. In the current coronavirus outbreak, companies and health authorities seek for solutions to monitor the presence of SARS-CoV-2 in their environments.
In a continued effort to help fight the COVID-19 crisis, Eurofins Technologies announces the CE-IVD marking of a first range of testing kits for serology-based antibody detection by ELISA of patients who have been exposed to COVID-19. The development of the assays has been spearheaded by affiliate companies Gold Standard Diagnostics Inc., VIROTECH Diagnostics GmbH, NovaTec Immundiagnostica GmbH and Ingenasa (Inmunologia Y Genetica Aplicada SA). Those specialized diagnostic technologies companies are well-established providers of testing solutions with a strong focus on scientific excellence in infectious diseases testing and immunology. To learn more about the new Immunoassays for diagnostic of exposure to COVID-19, visit
Eurofins Technologies, a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods, announces the launch of a range of testing kits for serology-based antibody detection by ELISA of patients who have been exposed to COVID-19. The development of the assays has been spearheaded by affiliate companies Gold Standard Diagnostics Inc., Virotech Diagnostics GmbH, NovaTec Immundiagnostica GmbH and Ingenasa (Inmunologia Y Genetica Aplicada SA). Those specialized diagnostic technologies companies are well-established providers of testing solutions with a strong focus on scientific excellence in infectious disease testing and immunology. The first ELISA assays are expected to receive the CE-IVD mark by 16 April 2020 and will also be submitted to the U.
Eurofins Technologies, a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods, has launched GeneScan VIRSeek SARS-CoV-2 RT-PCR, an integrated solution including RNA extraction and test kits based on real-time RT-PCR (Reverse transcription polymerase chain reaction) for the detection of SARS-CoV-2 in swabs of environmental surfaces. Recently published studies suggest that SARS-CoV-2 may remain viable on different surfaces for up to 72 hours. The comprehensive VIRSeek suite of test kits and workflows provides customers with fast tests to broadly screen for the presence of SARS-CoV-2, as well as verification of results with an independent test.
Validations are now available on new matrices for our ELISA tests H2DON and B ZERO® H2DON, Immunoenzymatic assays for quantitative detection of deoxynivalenol (vomitoxin), fully water-based.
Both assays are currently validated on:
Maize I Wheat I Durum wheat I Bran NEW! I Middlings NEW! I Whole and dehulled oats I Barley I Rye NEW! I DDGS I Swine feed I Brown rice I Corn gluten meal I Soybean meal